Clinical Commissioning Policy: Clofarabine for refractory or relapsed acute myeloid leukaemia (AML) as a bridge to stem cell transplantation (all ages)

Document first published:: 8 November 2018
Page updated:: 8 November 2018
Topic:: Commissioning, Specialised commissioning
Publication type:: Policy or strategy

NHS England will not routinely commission clofarabine for refractory or relapsed acute myeloid leukaemia (AML) as a bridge to stem cell transplantation in accordance with the criteria outlined in this document.

Document

$Clinical Commissioning Policy: Clofarabine for refractory or relapsed acute myeloid leukaemia (AML) as a bridge to stem cell transplantation (all ages)$

Clinical Commissioning Policy: Clofarabine for refractory or relapsed acute myeloid leukaemia (AML) as a bridge to stem cell transplantation (all ages)

PDF
387 KB
10 pages

Cookies on the NHS England website

Clinical Commissioning Policy: Clofarabine for refractory or relapsed acute myeloid leukaemia (AML) as a bridge to stem cell transplantation (all ages)